The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: From the laboratory to clinical practice

Annals of Oncology

Volumn 14, Issue 12, 2003, Pages 1705-1713

  Graziano, Frada ^a   Humar, B ^b   Guilford, P ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

E cadherin; Gastric cancer; Germline; Hereditary diffuse gastric cancer

Indexed keywords

APC PROTEIN; BETA CATENIN; CANCER GROWTH FACTOR; CYCLOOXYGENASE 2; DEATH RECEPTOR 5; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; INTERLEUKIN 1ALPHA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P14ARF; PROTEIN P16; PROTEIN TYROSINE KINASE; TRANSFORMING GROWTH FACTOR; TREFOIL PEPTIDE; UVOMORULIN;

ALLELE; BREAST CARCINOMA; CANCER PATIENT; CANCER SCREENING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; EXPERIMENTAL MODEL; GASTRECTOMY; GENE INACTIVATION; GENE SEQUENCE; GENE TARGETING; GENETIC IDENTIFICATION; GERM LINE; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; MISSENSE MUTATION; PATIENT SELECTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; STOMACH CANCER;

CADHERINS; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; PEDIGREE; STOMACH NEOPLASMS; SYNDROME;

EID: 0348229127     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg486     Document Type: Review

References (85)

1. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7: 619-627.
2. Moriyama N, Ishihara S, Hirose M et al. E-cadherin is essential for gastric epithelial restitution in vitro: a study using the normal rat gastric mucosal cell line RGM1. J Lab Clin Med 2001; 138: 236-242.
3. Del Buono R, Pignatelli M. The role of the E-cadherin complex in gastrointestinal cell differentiation. Cell Prolif 1999; 32: 79-84.
4. Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999; 18: 4301-4312.
5. Mayer B, Johnson JP, Leitl F et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993; 53: 1690-1695.
6. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999; 24: 73-76.
7. Vleminckx K, Vakaet L Jr, Mareel M et al. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-119.
8. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998; 12: 226-237.
9. El-Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002; 12: 128-140.
10. Oda T, Kanai Y, Oyama T et al. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 1994; 91: 1858-1862.
11. Becker KF, Hofler H. Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst 1995; 87: 1082-1084.
12. Chan AO, Luk JM, Hui WM, Lam SK. Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol 1999; 14: 1150-1160.
13. Becker KF, Atkinson MJ, Reich U et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-3852.
14. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405.
15. Gayther SA, Gorringe KL, Ram SJ et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998; 58: 4086-4089.
16. Richards FM, McKee SA, Rajpar MH et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999; 8: 607-610.
17. Salahshor S, Hou H, Diep CB et al. A germline E-cadherin mutation in a family with gastric and colon cancer. Int J Mol Med 2001; 8: 439-443.
18. Guilford PJ, Hopkins JB, Grady WM et al. E-cadherin germline, mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 1999; 14: 249-255.
19. Dunbier A, Guilford P. Hereditary diffuse gastric cancer. Adv Cancer Res 2001; 83: 55-65.
20. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. J Natl Cancer hist 1998; 90: 1039-1071.
21. Tamura G, Yin J, Wang S et al. E-cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Just 2000; 92: 569-573.
22. Lee TL, Leung WK, Chan MW et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002; 8: 1761-1766.
23. Grady WM, Willis J, Guilford PJ et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genet 2000; 26: 16-17.
24. Machado JC, Oliveira C, Carvalho R et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 2001; 20: 1525-1528.
25. To KF, Leung WK, Lee TL et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 2002; 102: 623-628.
26. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573-586.
27. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors - state of the art. Ann Oncol 2002; 13: 1699-1716.
28. Caldas C, Carneiro F, Lynch HT et al. Familial gastric cancer: overview and guidelines for management. J Med Genet 1999; 36: 873-880.
29. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121: 1348-1353.
30. Park JG, Yang HK, Kim WH et al. Report of the first meeting of the International Collaborative Group on Hereditary Gastric Cancer. J Natl Cancer Inst 2000; 92: 1781-1782.
31. Oliveira C, Bordin MC, Grehan N et al. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 2002; 19: 510-517.
32. Jonsson BA, Bergh A, Stattin P et al. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002; 98: 838-843.
33. Kusano M, Kakiuchi H, Mihara M et al. Absence of microsatellite instability and germline mutations of E-cadherin, APC and p53 genes in Japanese familial gastric cancer. Tumour Biol 2001; 22: 262-268.
34. Avizienyte E, Launonen V, Salovaara R et al. E-cadherin is not frequently mutated in hereditary gastric cancer. J Med Genet 2001; 38: 49-52.
35. Yoon KA, Ku JL, Yang HK et al. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 1999; 44: 177-180.
36. Stone J, Bevan S, Cunningham D et al. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer 1999; 79: 1935-1937.
37. Iida S, Akiyama Y, Ichikawa W et al. Infrequent germ-line mutation of the E-cadherin gene in Japanese familial gastric cancer kindreds. Clin Cancer Res 1999; 5: 1445-1447.
38. Graziano F, Ruzzo A, Bearzi I et al. Screening E-cadherin germline mutations in Italian patients with familial diffuse gastric cancer. An analysis in the District of Urbino, Region Marche, Central Italy. Tumori 2003; in press.
39. Berx G, Cleton-Jansen AM, Strumane K et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13: 1919-1925.
40. Chan JK, Wong CS. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv Anat Pathol 2001; 8: 165-172.
41. Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215: 267-279.
42. Hartmann LC, Sellers TA, Schaid DJ et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637.
43. King MC, Wieand S, Hale K et al. National Surgical Adjuvant Breast and Bowel Project. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001; 286: 2251-2256.
44. Ikonen T, Matikainen M, Mononen N et al. Association of E-cadherin germ-line alterations with prostate cancer. Clin Cancer Res 2001; 7: 3465-3471.
45. Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 1982; 82: 228-233.
46. Giarelli E. Prophylactic gastrectomy for CDH1 mutation carriers. Clin J Oncol Nurs 2002; 6: 161-162.
47. Lewis FR, Mellinger JD, Hayashi A et al. Prophylactic total gastrectomy for familial gastric cancer. Surgery 2001; 130: 612-617.
48. Chun YS, Lindor NM, Smyrk TC et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 2001; 92: 181-187.
49. Huntsman DG, Carneiro F, Lewis FR et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 2001; 344: 1904-1909.
50. Lynch HT, Grady W, Lynch JF et al. E-cadherin mutation-based genetic counseling and hereditary diffuse gastric carcinoma. Cancer Genet Cytogenet 2000; 122: 1-6.
51. Brennan MF, Karpeh MS Jr. Surgery for gastric cancer: the American view. Semin Oncol 1996; 23: 352-354.
52. Hippo Y, Taniguchi H, Tsutsumi S et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002; 62: 233-240.
53. Handschuh G, Luber B, Hutzler P et al. Single amino acid substitutions in conserved extracellular domains of E-cadherin differ in their functional consequences. J Mol Biol 2001; 314: 445-454.
54. Dussaulx-Garin L, Blayau M, Pagenault M et al. A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol 2001; 13: 711-715.
55. Kim HC, Wheeler JM, Kim JC et al. The E-cadherin gene (CDH1) variants T340A and L599V in gastric and colorectal cancer patients in Korea. Gut 2000; 47: 262-267.
56. Yabuta T, Shinmura K, Tani M et al. E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. Int J Cancer 2002; 101: 434-441.
57. Becker KF, Reich U, Schott C, Hofler H. Single nucleotide polymorphisms in the human E-cadherin gene. Hum Genet 1995; 96: 739-740.
58. Suriano G, Oliveira C, Ferreira P et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet 2003; 12: 575-582.
59. Humar B, Toro T, Graziano F et al. Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat 2002; 19: 518-525.
60. Nakamura A, Shimazaki T, Kaneko K et al. Characterization of DNA polymorphisms in the E-cadherin gene (CDH1) promoter region. Mutat Res 2002; 502: 19-24.
61. Li LC, Chui RM, Sasaki M et al. A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 2000; 71: 873-877.
62. Graziano F, Humar B, Catalano V et al. An analysis of the C/A polymorphism at position - 160 of the E-cadherin gene (CDH1) promoter. Potential role for diffuse gastric cancer susceptibility: Ann Oncol 2002; 13 (Suppl 5): 13 (Abstr 43).
63. Wu MS, Huang SP, Chang YT et al. Association of the - 160 C/A promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 2002; 94: 1443-1448.
64. Pharoah PD, Oliveira C, Machado JC et al. CDH1 c-160a promoter polymorphism is not associated with risk of stomach cancer. Int J Cancer 2002; 101: 198-197.
65. Humar B, Graziano F, Cascinu S et al. Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 2002; 21: 8192-8195.
66. Hanby AM, Chinery R, Poulsom R et al. Downregulation of E-cadherin in the reparative epithelium of the human gastrointestinal tract. Am J Pathol 1996; 148: 723-729.
67. Terres AM, Pajares JM, O'Toole D et al. H. pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J Clin Pathol 1998; 51: 410-412.
68. Conacci-Sorrell M, Zhurinsky J, BeD-Ze'ev A. The cadherin-catenin adhesion system in signalling and cancer. J Clin Invest 2002; 109: 987-991.
69. Roura S, Miravet S, Piedra J et al. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem 1999; 274: 36734-36740.
70. Thiery JP, Chopin D. Epithelial cell plasticity in development and tumor progression. Cancer Metastasis Rev 1999; 18: 31-42.
71. Carpenter PM, Al-Kuran RA, Theuer CP. Paranuclear E-cadherin in gastric adenocarcinoma. Am J Clin Pathol 2002; 118: 887-894.
72. Batlle E, Sancho E, Franci C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2: 84-89.
73. Cano A, Perez-Moreno MA, Rodrigo I et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
74. Potla L, Boghaert ER, Armellino D et al. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett 2002; 175: 187-195.
75. Kamei T, Matozaki T, Sakisaka T et al. Coendocytosis of cadherin and c-Met coupled to disruption of cell-cell adhesion in MDCK cells - regulation by Rho, Rac and Rab small G proteins. Oncogene 1999; 18: 6776-6784.
76. St Croix B, Sheehan C, Rak JW et al. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998; 142: 557-571.
77. Symons JR, LeVea CM, Mooney RA. Expression of the leucocyte common antigen-related (LAR) tyrosine phosphatase is regulated by cell density through functional E-cadherin complexes. Biochem J 2002; 15: 513-519.
78. Rosivatz E, Becker I, Specht K et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891.
79. Van Golen KL, Bao LW, Pan Q et al. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis 2002; 19: 301-311.
80. Braga VM, Machesky LM, Hall A, Hotchin NA. The small GTPases Rho and Rac are required for the establishment of cadherin-dependent cell - cell contacts. J Cell Biol 1997; 137: 1421-1431.
81. Thoreson MA, Reynolds AB. Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 2002; 70: 583-589.
82. Aono S, Nakagawa S, Reynolds AB, Takeichi M. p120(ctn) acts as an inhibitory regulator of cadherin function in colon carcinoma cells. J Cell Biol 1999; 145: 551-562.
83. Anastasiadis PZ, Moon SY, Thoreson MA et al. Inhibition of RhoA by p120 catenin. Nat Cell Biol 2000; 2: 637-644.
84. Kovacs EM, Ali RG, McCormack AJ, Yap AS. E-cadherin homophilic ligation directly signals through Rac and phosphatidylinositol 3-kinase to regulate adhesive contacts. Biol Chem 2002; 277: 6708-6718.
85. Nakagawa M, Fukata M, Yamaga M et al. Recruitment and activation of Rac1 by the formation of E-cadherin-mediated cell-cell adhesion sites. J Cell Sci 2001; 114: 1829-1838.